Xenon Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is a neuroscience-focused, clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics for patients suffering from neurological and psychiatric disorders. The company's primary therapeutic focus is on epilepsy and depression, utilizing its deep expertise in ion channel biology. Xenon's lead clinical candidate is azetukalner (formerly XEN1101), a novel, highly potent, and selective Kv7 potassium channel opener. Azetukalner is currently being evaluated in multiple late-stage clinical trials, including Phase 3 programs for focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), major depressive disorder (MDD), and bipolar depression (BPD).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead Kv7 potassium channel opener, azetukalner, across multiple indications including focal onset seizures (Phase 3), primary generalized tonic-clonic seizures (Phase 3 X-ACKT), major depressive disorder (Phase 3 X-NOVA2 and X-NOVA3), and bipolar depression (Phase 3 X-CEED).
Expected impact: Establishes a multi-indication franchise with blockbuster peak-sales potential exceeding $2 billion.
Developing next-generation selective ion channel modulators for pain management, including XEN1701 (targeting NaV1.7) and XEN1120 (targeting Kv7), both currently in Phase 1 clinical trials.
Expected impact: Provides non-opioid therapeutic alternatives for acute and chronic pain, diversifying the clinical pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating on the development of NBI-921355, an investigational selective inhibitor of NaV1.2 and NaV1.6 sodium channels for the treatment of certain types of epilepsy.
Terms: Xenon received a $50 million upfront payment (including a $20 million equity investment) and is eligible for up to $1.7 billion in potential development, regulatory, and commercial milestones, plus royalties. A $7.5 million milestone was recognized in Q1 2025.